This paper provides an overview of the current position of drug and alcohol services in Scotland and summarises the progress against recommendations made in our 2009 report (Audit Scotland)
Bibliography: Domestic Policy Issues
Drugs policy inquiry – publications
Inquiry launched on Monday 4 February 2019. The closing date for written submissions was Monday 18 March 2019 (Parliament UK)
Misuse of illicit drugs and medicines: applying All Our Health
Evidence and guidance to help health professionals identify, prevent or reduce drug-related harm (Public Health England)
Alcohol and other drug treatment services in Australia 2017–18: key findings
In 2017–18, 952 publicly-funded alcohol and other drug treatment services provided just under 210,000 treatment episodes to an estimated 130,000 clients. The four most common drugs that led clients to seek treatment were alcohol (34% of all treatment episodes), amphetamines (25%), cannabis (21%) and heroin (5%). Two-thirds (66%) of all clients receiving treatment were male and the median age of clients was 34 years (AIHW)
Cannabis policy and legislation in the Nordic countries
The Nordic Welfare Centre´s new report Cannabis policy and legislation in the Nordic countries looks at the similarities and differences in legislation and the ways in which the law is enacted in legal practice, police work, and other arenas
National Prison Drugs Strategy
Ministry of Justice and Her Majesty’s Prison and Probation Service Prison Drugs Strategy
Control of pregabalin and gabapentin under the Misuse of Drugs Act 1971
This circular draws attention to the contents of the below Statutory Instruments (SIs), S.I. 2018/1356 and 2018/1383, which will come into force at 00.01 on 1 April 2019 (Home Office)
Supervised Drug Consumption Facilities Bill
1 Safe drug consumption facilities
2 Licence for provision of safe drug consumption facilities
3 Amendments to the Misuse of Drugs Act 1971
4 Annual report
5 Regulations
6 Financial provisions
7 Extent, commencement and short title
DrugScope Library Wellcome
This is a collection of grey literature and some archive material relating to drugs and drug policy, originally part of the library holdings at DrugScope (Wellcome)
Cannabis-based products for medicinal use in humans: commission to the ACMD
The Home Secretary has formally commissioned the Advisory Council on the Misuse of Drugs (ACMD) to conduct a longer-term review of cannabis-based products for medicinal use
National Drug Control Strategy (PDF)
A Report by the Office of National Drug Control Policy
Statement from FDA Commissioner Scott Gottlieb, M.D., on unprecedented new efforts to support development of over-the-counter naloxone to help reduce opioid overdose deaths
With the number of overdose deaths involving prescription and illicit opioids more than doubling over the last seven years to nearly 48,000 in 2017, it’s critical that we continue to address this tragedy from all fronts. This includes new ways to increase availability of naloxone, a drug used to treat opioid overdose (FDA)
Review of the New Strategic Direction for Alcohol and Drugs – Phase 2
A report prepared for the Department of Health in Northern Ireland by the Institute of Public Health in Ireland (PDF)
State of the Nation 2018
The New Zealand Drug Foundation’s State of the Nation report is a snapshot of how New Zealand is dealing with alcohol and other drugs
Colorado publishes latest statistics on impact of cannabis legalisation
The state government instructed the state Department of Public Safety to report on key statistics of cannabis-related topics including crime, impaired driving, hospital visits, usage rates, effects on youth. A second biennial report was released in October 2018 (EMCDDA)
Considering Heroin-Assisted Treatment and Supervised Drug Consumption Sites in the United States
Data for 2017 indicate that there were more than 47,000 opioid-involved overdose deaths, and one in eight adults now reports having had a family member or close friend die from opioids. Increasing the availability and reducing the costs of approved medications for those with an opioid use disorder (OUD) is imperative; however, jurisdictions addressing OUDs and overdose may wish to consider additional interventions. Download (RAND)
He Ara Oranga : Report of the Government Inquiry into Mental Health and Addiction
The Inquiry Panel wanted to set a clear direction for the next five to ten years that Government, the mental health and addiction sectors and the whole community can pick up and make happen. Our purpose was to identify unmet needs and develop recommendations for a better mental health and addiction system for Aotearoa New Zealand
Guidance for drug and alcohol treatment providers and clients
Guidelines for drug and alcohol treatment providers on sharing client’s information with the National Drug and alcohol Treatment Monitoring System (NDTMS)
Review of the Psychoactive Substances Act 2016
This review sought to measure changes in outcomes before and after the implementation of the Act, to provide an indication of whether its aims are being achieved (Home Office)
Cannabis-based products for medicinal use: Guidance to clinicians
Following the Government’s announcement to reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 16
- Next Page »
